nodes	percent_of_prediction	percent_of_DWPC	metapath
Aripiprazole—CYP3A5—prostate cancer	0.161	0.698	CbGaD
Aripiprazole—CYP3A4—prostate cancer	0.0696	0.302	CbGaD
Aripiprazole—CYP3A5—Flutamide—prostate cancer	0.0232	0.0684	CbGbCtD
Aripiprazole—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0208	0.0613	CbGbCtD
Aripiprazole—CYP2D6—Bicalutamide—prostate cancer	0.0172	0.0506	CbGbCtD
Aripiprazole—CYP3A5—Cabazitaxel—prostate cancer	0.0172	0.0506	CbGbCtD
Aripiprazole—ABCB1—Estramustine—prostate cancer	0.017	0.05	CbGbCtD
Aripiprazole—CYP3A5—Estrone—prostate cancer	0.0168	0.0495	CbGbCtD
Aripiprazole—CYP2D6—Abiraterone—prostate cancer	0.0143	0.042	CbGbCtD
Aripiprazole—CYP3A7—Estradiol—prostate cancer	0.0129	0.0379	CbGbCtD
Aripiprazole—CYP3A7-CYP3A51P—Estradiol—prostate cancer	0.0129	0.0379	CbGbCtD
Aripiprazole—ADRA1B—vas deferens—prostate cancer	0.0123	0.205	CbGeAlD
Aripiprazole—ABCB1—Cabazitaxel—prostate cancer	0.0112	0.0329	CbGbCtD
Aripiprazole—CYP3A4—Bicalutamide—prostate cancer	0.0109	0.0322	CbGbCtD
Aripiprazole—ABCB1—Estrone—prostate cancer	0.0109	0.0322	CbGbCtD
Aripiprazole—CYP3A4—Estramustine—prostate cancer	0.0102	0.0299	CbGbCtD
Aripiprazole—ABCB1—Ethinyl Estradiol—prostate cancer	0.00975	0.0287	CbGbCtD
Aripiprazole—CYP3A5—Estradiol—prostate cancer	0.00965	0.0284	CbGbCtD
Aripiprazole—CYP3A4—Abiraterone—prostate cancer	0.00906	0.0267	CbGbCtD
Aripiprazole—CYP3A4—Flutamide—prostate cancer	0.00906	0.0267	CbGbCtD
Aripiprazole—CYP3A7-CYP3A51P—Docetaxel—prostate cancer	0.00769	0.0226	CbGbCtD
Aripiprazole—CYP3A7—Docetaxel—prostate cancer	0.00769	0.0226	CbGbCtD
Aripiprazole—HTR7—vas deferens—prostate cancer	0.00717	0.12	CbGeAlD
Aripiprazole—ABCB1—Conjugated Estrogens—prostate cancer	0.00715	0.0211	CbGbCtD
Aripiprazole—CYP3A4—Cabazitaxel—prostate cancer	0.0067	0.0197	CbGbCtD
Aripiprazole—CYP3A4—Estrone—prostate cancer	0.00655	0.0193	CbGbCtD
Aripiprazole—ABCB1—Mitoxantrone—prostate cancer	0.0065	0.0191	CbGbCtD
Aripiprazole—CYP3A5—Etoposide—prostate cancer	0.0063	0.0186	CbGbCtD
Aripiprazole—ABCB1—Estradiol—prostate cancer	0.00628	0.0185	CbGbCtD
Aripiprazole—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00584	0.0172	CbGbCtD
Aripiprazole—CHRM3—ureter—prostate cancer	0.00577	0.0963	CbGeAlD
Aripiprazole—CYP3A5—Docetaxel—prostate cancer	0.00577	0.017	CbGbCtD
Aripiprazole—ABCB1—Prednisone—prostate cancer	0.0054	0.0159	CbGbCtD
Aripiprazole—CYP3A4—Conjugated Estrogens—prostate cancer	0.00429	0.0126	CbGbCtD
Aripiprazole—H1F0—semen—prostate cancer	0.00414	0.0691	CbGeAlD
Aripiprazole—ABCB1—Etoposide—prostate cancer	0.0041	0.0121	CbGbCtD
Aripiprazole—CYP3A4—Mitoxantrone—prostate cancer	0.0039	0.0115	CbGbCtD
Aripiprazole—CYP3A4—Estradiol—prostate cancer	0.00376	0.0111	CbGbCtD
Aripiprazole—ABCB1—Docetaxel—prostate cancer	0.00375	0.011	CbGbCtD
Aripiprazole—CYP3A4—Prednisone—prostate cancer	0.00324	0.00953	CbGbCtD
Aripiprazole—ABCB1—Doxorubicin—prostate cancer	0.0028	0.00823	CbGbCtD
Aripiprazole—CYP2D6—Doxorubicin—prostate cancer	0.00264	0.00776	CbGbCtD
Aripiprazole—CYP3A4—Etoposide—prostate cancer	0.00246	0.00723	CbGbCtD
Aripiprazole—CYP3A4—Docetaxel—prostate cancer	0.00225	0.00662	CbGbCtD
Aripiprazole—CYP3A4—Doxorubicin—prostate cancer	0.00168	0.00493	CbGbCtD
Aripiprazole—HTR2A—urine—prostate cancer	0.00111	0.0186	CbGeAlD
Aripiprazole—H1F0—prostate gland—prostate cancer	0.00104	0.0173	CbGeAlD
Aripiprazole—CYP3A4—urine—prostate cancer	0.00103	0.0172	CbGeAlD
Aripiprazole—CYP2D6—urine—prostate cancer	0.00101	0.0169	CbGeAlD
Aripiprazole—Vilazodone—CYP2C18—prostate cancer	0.000932	0.214	CrCbGaD
Aripiprazole—DRD4—testis—prostate cancer	0.000897	0.015	CbGeAlD
Aripiprazole—CHRM5—epithelium—prostate cancer	0.000884	0.0148	CbGeAlD
Aripiprazole—H1F0—seminal vesicle—prostate cancer	0.000878	0.0146	CbGeAlD
Aripiprazole—CHRM2—prostate gland—prostate cancer	0.000826	0.0138	CbGeAlD
Aripiprazole—ADRB1—prostate gland—prostate cancer	0.000781	0.013	CbGeAlD
Aripiprazole—CHRM1—prostate gland—prostate cancer	0.000752	0.0125	CbGeAlD
Aripiprazole—ADRA1B—renal system—prostate cancer	0.000749	0.0125	CbGeAlD
Aripiprazole—Cilostazol—CYP3A5—prostate cancer	0.000722	0.165	CrCbGaD
Aripiprazole—H1F0—renal system—prostate cancer	0.000707	0.0118	CbGeAlD
Aripiprazole—H1F0—urethra—prostate cancer	0.000695	0.0116	CbGeAlD
Aripiprazole—CHRM4—testis—prostate cancer	0.000678	0.0113	CbGeAlD
Aripiprazole—CHRM3—prostate gland—prostate cancer	0.000673	0.0112	CbGeAlD
Aripiprazole—ADRA1A—prostate gland—prostate cancer	0.000618	0.0103	CbGeAlD
Aripiprazole—KCNH2—prostate gland—prostate cancer	0.000597	0.00996	CbGeAlD
Aripiprazole—ADRA2C—prostate gland—prostate cancer	0.000589	0.00982	CbGeAlD
Aripiprazole—H1F0—bone marrow—prostate cancer	0.000535	0.00893	CbGeAlD
Aripiprazole—KCNH2—seminal vesicle—prostate cancer	0.000505	0.00842	CbGeAlD
Aripiprazole—ADRA2C—seminal vesicle—prostate cancer	0.000498	0.00831	CbGeAlD
Aripiprazole—CYP3A5—prostate gland—prostate cancer	0.000493	0.00822	CbGeAlD
Aripiprazole—Cilostazol—CYP2C19—prostate cancer	0.000492	0.113	CrCbGaD
Aripiprazole—HRH1—prostate gland—prostate cancer	0.000478	0.00798	CbGeAlD
Aripiprazole—HTR7—epithelium—prostate cancer	0.000471	0.00785	CbGeAlD
Aripiprazole—ADRA2A—prostate gland—prostate cancer	0.00047	0.00784	CbGeAlD
Aripiprazole—CHRM3—renal system—prostate cancer	0.000459	0.00765	CbGeAlD
Aripiprazole—H1F0—testis—prostate cancer	0.000457	0.00763	CbGeAlD
Aripiprazole—HTR1A—renal system—prostate cancer	0.000457	0.00762	CbGeAlD
Aripiprazole—ADRA1A—epithelium—prostate cancer	0.000454	0.00757	CbGeAlD
Aripiprazole—CHRM3—urethra—prostate cancer	0.00045	0.00752	CbGeAlD
Aripiprazole—HTR7—renal system—prostate cancer	0.000437	0.00728	CbGeAlD
Aripiprazole—ADRA1A—renal system—prostate cancer	0.000421	0.00703	CbGeAlD
Aripiprazole—KCNH2—renal system—prostate cancer	0.000407	0.00679	CbGeAlD
Aripiprazole—ADRA2C—renal system—prostate cancer	0.000401	0.0067	CbGeAlD
Aripiprazole—KCNH2—urethra—prostate cancer	0.000399	0.00667	CbGeAlD
Aripiprazole—ADRA2A—seminal vesicle—prostate cancer	0.000397	0.00663	CbGeAlD
Aripiprazole—ADRA2C—urethra—prostate cancer	0.000394	0.00658	CbGeAlD
Aripiprazole—Perphenazine—AOX1—prostate cancer	0.000393	0.09	CrCbGaD
Aripiprazole—HRH1—epithelium—prostate cancer	0.000351	0.00586	CbGeAlD
Aripiprazole—CYP3A5—renal system—prostate cancer	0.000336	0.0056	CbGeAlD
Aripiprazole—H1F0—lymph node—prostate cancer	0.000331	0.00553	CbGeAlD
Aripiprazole—HRH1—urethra—prostate cancer	0.00032	0.00534	CbGeAlD
Aripiprazole—ADRA2A—urethra—prostate cancer	0.000314	0.00525	CbGeAlD
Aripiprazole—Cilostazol—CYP3A4—prostate cancer	0.000313	0.0716	CrCbGaD
Aripiprazole—KCNH2—bone marrow—prostate cancer	0.000307	0.00513	CbGeAlD
Aripiprazole—CHRM3—testis—prostate cancer	0.000296	0.00495	CbGeAlD
Aripiprazole—HTR2A—epithelium—prostate cancer	0.000293	0.0049	CbGeAlD
Aripiprazole—HTR7—testis—prostate cancer	0.000282	0.00471	CbGeAlD
Aripiprazole—HTR2A—renal system—prostate cancer	0.000272	0.00454	CbGeAlD
Aripiprazole—DRD2—testis—prostate cancer	0.000267	0.00445	CbGeAlD
Aripiprazole—Vilazodone—CYP3A4—prostate cancer	0.000266	0.0609	CrCbGaD
Aripiprazole—KCNH2—testis—prostate cancer	0.000263	0.00439	CbGeAlD
Aripiprazole—ABCB1—prostate gland—prostate cancer	0.000262	0.00437	CbGeAlD
Aripiprazole—ADRA2C—testis—prostate cancer	0.000259	0.00433	CbGeAlD
Aripiprazole—CYP3A4—renal system—prostate cancer	0.000252	0.00421	CbGeAlD
Aripiprazole—CYP2D6—renal system—prostate cancer	0.000248	0.00414	CbGeAlD
Aripiprazole—HTR2B—lymph node—prostate cancer	0.000239	0.00399	CbGeAlD
Aripiprazole—Ziprasidone—CYP3A5—prostate cancer	0.000233	0.0533	CrCbGaD
Aripiprazole—ABCB1—seminal vesicle—prostate cancer	0.000221	0.00369	CbGeAlD
Aripiprazole—HRH1—testis—prostate cancer	0.000211	0.00352	CbGeAlD
Aripiprazole—ADRA2A—testis—prostate cancer	0.000207	0.00345	CbGeAlD
Aripiprazole—Nefazodone—CYP3A5—prostate cancer	0.000195	0.0448	CrCbGaD
Aripiprazole—ABCB1—epithelium—prostate cancer	0.000192	0.00321	CbGeAlD
Aripiprazole—KCNH2—lymph node—prostate cancer	0.000191	0.00318	CbGeAlD
Aripiprazole—ADRA2C—lymph node—prostate cancer	0.000188	0.00314	CbGeAlD
Aripiprazole—Trazodone—CYP3A5—prostate cancer	0.000181	0.0414	CrCbGaD
Aripiprazole—ABCB1—renal system—prostate cancer	0.000178	0.00298	CbGeAlD
Aripiprazole—HTR2A—testis—prostate cancer	0.000176	0.00294	CbGeAlD
Aripiprazole—Perphenazine—CYP2C18—prostate cancer	0.000176	0.0403	CrCbGaD
Aripiprazole—ABCB1—urethra—prostate cancer	0.000175	0.00292	CbGeAlD
Aripiprazole—CYP2D6—testis—prostate cancer	0.00016	0.00267	CbGeAlD
Aripiprazole—HRH1—lymph node—prostate cancer	0.000153	0.00255	CbGeAlD
Aripiprazole—ADRA2A—lymph node—prostate cancer	0.00015	0.0025	CbGeAlD
Aripiprazole—ABCB1—bone marrow—prostate cancer	0.000135	0.00225	CbGeAlD
Aripiprazole—ABCB1—testis—prostate cancer	0.000115	0.00192	CbGeAlD
Aripiprazole—Ziprasidone—CYP3A4—prostate cancer	0.000101	0.0231	CrCbGaD
Aripiprazole—Nefazodone—CYP3A4—prostate cancer	8.46e-05	0.0194	CrCbGaD
Aripiprazole—ABCB1—lymph node—prostate cancer	8.36e-05	0.00139	CbGeAlD
Aripiprazole—Perphenazine—CYP2C19—prostate cancer	7.88e-05	0.0181	CrCbGaD
Aripiprazole—Trazodone—CYP3A4—prostate cancer	7.83e-05	0.0179	CrCbGaD
Aripiprazole—Prochlorperazine—CYP3A4—prostate cancer	7.01e-05	0.0161	CrCbGaD
Aripiprazole—Perphenazine—CYP3A4—prostate cancer	5.01e-05	0.0115	CrCbGaD
Aripiprazole—Eye disorder—Epirubicin—prostate cancer	1.65e-05	6.71e-05	CcSEcCtD
Aripiprazole—Hypersensitivity—Etoposide—prostate cancer	1.65e-05	6.71e-05	CcSEcCtD
Aripiprazole—Tinnitus—Epirubicin—prostate cancer	1.65e-05	6.7e-05	CcSEcCtD
Aripiprazole—Haemoglobin—Doxorubicin—prostate cancer	1.64e-05	6.68e-05	CcSEcCtD
Aripiprazole—Musculoskeletal discomfort—Capecitabine—prostate cancer	1.64e-05	6.68e-05	CcSEcCtD
Aripiprazole—Flushing—Epirubicin—prostate cancer	1.64e-05	6.67e-05	CcSEcCtD
Aripiprazole—Cardiac disorder—Epirubicin—prostate cancer	1.64e-05	6.67e-05	CcSEcCtD
Aripiprazole—Rhinitis—Doxorubicin—prostate cancer	1.64e-05	6.66e-05	CcSEcCtD
Aripiprazole—Dyspepsia—Docetaxel—prostate cancer	1.64e-05	6.66e-05	CcSEcCtD
Aripiprazole—Haemorrhage—Doxorubicin—prostate cancer	1.63e-05	6.65e-05	CcSEcCtD
Aripiprazole—Hepatitis—Doxorubicin—prostate cancer	1.63e-05	6.65e-05	CcSEcCtD
Aripiprazole—Insomnia—Capecitabine—prostate cancer	1.63e-05	6.63e-05	CcSEcCtD
Aripiprazole—Hypoaesthesia—Doxorubicin—prostate cancer	1.62e-05	6.61e-05	CcSEcCtD
Aripiprazole—Pharyngitis—Doxorubicin—prostate cancer	1.62e-05	6.6e-05	CcSEcCtD
Aripiprazole—Paraesthesia—Capecitabine—prostate cancer	1.62e-05	6.58e-05	CcSEcCtD
Aripiprazole—Decreased appetite—Docetaxel—prostate cancer	1.62e-05	6.58e-05	CcSEcCtD
Aripiprazole—Urinary tract disorder—Doxorubicin—prostate cancer	1.61e-05	6.57e-05	CcSEcCtD
Aripiprazole—Oedema peripheral—Doxorubicin—prostate cancer	1.61e-05	6.55e-05	CcSEcCtD
Aripiprazole—Gastrointestinal disorder—Docetaxel—prostate cancer	1.61e-05	6.53e-05	CcSEcCtD
Aripiprazole—Asthenia—Etoposide—prostate cancer	1.61e-05	6.53e-05	CcSEcCtD
Aripiprazole—Connective tissue disorder—Doxorubicin—prostate cancer	1.6e-05	6.53e-05	CcSEcCtD
Aripiprazole—Dyspnoea—Capecitabine—prostate cancer	1.6e-05	6.53e-05	CcSEcCtD
Aripiprazole—Anaphylactic shock—Prednisone—prostate cancer	1.6e-05	6.53e-05	CcSEcCtD
Aripiprazole—Oedema—Prednisone—prostate cancer	1.6e-05	6.53e-05	CcSEcCtD
Aripiprazole—Fatigue—Docetaxel—prostate cancer	1.6e-05	6.52e-05	CcSEcCtD
Aripiprazole—Angiopathy—Epirubicin—prostate cancer	1.6e-05	6.52e-05	CcSEcCtD
Aripiprazole—Urethral disorder—Doxorubicin—prostate cancer	1.6e-05	6.52e-05	CcSEcCtD
Aripiprazole—Nausea—Mitoxantrone—prostate cancer	1.6e-05	6.5e-05	CcSEcCtD
Aripiprazole—Immune system disorder—Epirubicin—prostate cancer	1.59e-05	6.49e-05	CcSEcCtD
Aripiprazole—Infection—Prednisone—prostate cancer	1.59e-05	6.48e-05	CcSEcCtD
Aripiprazole—Mediastinal disorder—Epirubicin—prostate cancer	1.59e-05	6.48e-05	CcSEcCtD
Aripiprazole—Pain—Docetaxel—prostate cancer	1.59e-05	6.47e-05	CcSEcCtD
Aripiprazole—Constipation—Docetaxel—prostate cancer	1.59e-05	6.47e-05	CcSEcCtD
Aripiprazole—Dyspepsia—Capecitabine—prostate cancer	1.58e-05	6.45e-05	CcSEcCtD
Aripiprazole—Chills—Epirubicin—prostate cancer	1.58e-05	6.45e-05	CcSEcCtD
Aripiprazole—Pruritus—Etoposide—prostate cancer	1.58e-05	6.44e-05	CcSEcCtD
Aripiprazole—Shock—Prednisone—prostate cancer	1.58e-05	6.42e-05	CcSEcCtD
Aripiprazole—Visual impairment—Doxorubicin—prostate cancer	1.57e-05	6.41e-05	CcSEcCtD
Aripiprazole—Nervous system disorder—Prednisone—prostate cancer	1.57e-05	6.4e-05	CcSEcCtD
Aripiprazole—Tachycardia—Prednisone—prostate cancer	1.56e-05	6.37e-05	CcSEcCtD
Aripiprazole—Decreased appetite—Capecitabine—prostate cancer	1.56e-05	6.37e-05	CcSEcCtD
Aripiprazole—Alopecia—Epirubicin—prostate cancer	1.56e-05	6.35e-05	CcSEcCtD
Aripiprazole—Skin disorder—Prednisone—prostate cancer	1.56e-05	6.34e-05	CcSEcCtD
Aripiprazole—Gastrointestinal disorder—Capecitabine—prostate cancer	1.55e-05	6.33e-05	CcSEcCtD
Aripiprazole—Fatigue—Capecitabine—prostate cancer	1.55e-05	6.32e-05	CcSEcCtD
Aripiprazole—Hyperhidrosis—Prednisone—prostate cancer	1.55e-05	6.31e-05	CcSEcCtD
Aripiprazole—Mental disorder—Epirubicin—prostate cancer	1.55e-05	6.29e-05	CcSEcCtD
Aripiprazole—Constipation—Capecitabine—prostate cancer	1.54e-05	6.27e-05	CcSEcCtD
Aripiprazole—Pain—Capecitabine—prostate cancer	1.54e-05	6.27e-05	CcSEcCtD
Aripiprazole—Malnutrition—Epirubicin—prostate cancer	1.54e-05	6.25e-05	CcSEcCtD
Aripiprazole—Erythema—Epirubicin—prostate cancer	1.54e-05	6.25e-05	CcSEcCtD
Aripiprazole—Feeling abnormal—Docetaxel—prostate cancer	1.53e-05	6.24e-05	CcSEcCtD
Aripiprazole—Diarrhoea—Etoposide—prostate cancer	1.53e-05	6.23e-05	CcSEcCtD
Aripiprazole—Anorexia—Prednisone—prostate cancer	1.53e-05	6.22e-05	CcSEcCtD
Aripiprazole—Eye disorder—Doxorubicin—prostate cancer	1.53e-05	6.21e-05	CcSEcCtD
Aripiprazole—Tinnitus—Doxorubicin—prostate cancer	1.52e-05	6.2e-05	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Docetaxel—prostate cancer	1.52e-05	6.19e-05	CcSEcCtD
Aripiprazole—Cardiac disorder—Doxorubicin—prostate cancer	1.52e-05	6.17e-05	CcSEcCtD
Aripiprazole—Flushing—Doxorubicin—prostate cancer	1.52e-05	6.17e-05	CcSEcCtD
Aripiprazole—Flatulence—Epirubicin—prostate cancer	1.51e-05	6.16e-05	CcSEcCtD
Aripiprazole—Tension—Epirubicin—prostate cancer	1.51e-05	6.14e-05	CcSEcCtD
Aripiprazole—Dysgeusia—Epirubicin—prostate cancer	1.5e-05	6.12e-05	CcSEcCtD
Aripiprazole—Nervousness—Epirubicin—prostate cancer	1.49e-05	6.07e-05	CcSEcCtD
Aripiprazole—Back pain—Epirubicin—prostate cancer	1.49e-05	6.05e-05	CcSEcCtD
Aripiprazole—Feeling abnormal—Capecitabine—prostate cancer	1.48e-05	6.04e-05	CcSEcCtD
Aripiprazole—Angiopathy—Doxorubicin—prostate cancer	1.48e-05	6.03e-05	CcSEcCtD
Aripiprazole—Dizziness—Etoposide—prostate cancer	1.48e-05	6.02e-05	CcSEcCtD
Aripiprazole—Muscle spasms—Epirubicin—prostate cancer	1.48e-05	6.01e-05	CcSEcCtD
Aripiprazole—Immune system disorder—Doxorubicin—prostate cancer	1.48e-05	6e-05	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Capecitabine—prostate cancer	1.47e-05	5.99e-05	CcSEcCtD
Aripiprazole—Mediastinal disorder—Doxorubicin—prostate cancer	1.47e-05	5.99e-05	CcSEcCtD
Aripiprazole—Abdominal pain—Docetaxel—prostate cancer	1.47e-05	5.98e-05	CcSEcCtD
Aripiprazole—Body temperature increased—Docetaxel—prostate cancer	1.47e-05	5.98e-05	CcSEcCtD
Aripiprazole—Chills—Doxorubicin—prostate cancer	1.47e-05	5.96e-05	CcSEcCtD
Aripiprazole—Musculoskeletal discomfort—Prednisone—prostate cancer	1.46e-05	5.95e-05	CcSEcCtD
Aripiprazole—Insomnia—Prednisone—prostate cancer	1.45e-05	5.9e-05	CcSEcCtD
Aripiprazole—Vision blurred—Epirubicin—prostate cancer	1.45e-05	5.89e-05	CcSEcCtD
Aripiprazole—Alopecia—Doxorubicin—prostate cancer	1.44e-05	5.87e-05	CcSEcCtD
Aripiprazole—Paraesthesia—Prednisone—prostate cancer	1.44e-05	5.86e-05	CcSEcCtD
Aripiprazole—Mental disorder—Doxorubicin—prostate cancer	1.43e-05	5.82e-05	CcSEcCtD
Aripiprazole—Urticaria—Capecitabine—prostate cancer	1.43e-05	5.82e-05	CcSEcCtD
Aripiprazole—Ill-defined disorder—Epirubicin—prostate cancer	1.43e-05	5.8e-05	CcSEcCtD
Aripiprazole—Abdominal pain—Capecitabine—prostate cancer	1.42e-05	5.79e-05	CcSEcCtD
Aripiprazole—Body temperature increased—Capecitabine—prostate cancer	1.42e-05	5.79e-05	CcSEcCtD
Aripiprazole—Vomiting—Etoposide—prostate cancer	1.42e-05	5.79e-05	CcSEcCtD
Aripiprazole—Malnutrition—Doxorubicin—prostate cancer	1.42e-05	5.79e-05	CcSEcCtD
Aripiprazole—Erythema—Doxorubicin—prostate cancer	1.42e-05	5.79e-05	CcSEcCtD
Aripiprazole—Anaemia—Epirubicin—prostate cancer	1.42e-05	5.78e-05	CcSEcCtD
Aripiprazole—Agitation—Epirubicin—prostate cancer	1.41e-05	5.75e-05	CcSEcCtD
Aripiprazole—Dyspepsia—Prednisone—prostate cancer	1.41e-05	5.74e-05	CcSEcCtD
Aripiprazole—Rash—Etoposide—prostate cancer	1.41e-05	5.74e-05	CcSEcCtD
Aripiprazole—Dermatitis—Etoposide—prostate cancer	1.41e-05	5.74e-05	CcSEcCtD
Aripiprazole—Headache—Etoposide—prostate cancer	1.4e-05	5.7e-05	CcSEcCtD
Aripiprazole—Flatulence—Doxorubicin—prostate cancer	1.4e-05	5.7e-05	CcSEcCtD
Aripiprazole—Tension—Doxorubicin—prostate cancer	1.4e-05	5.68e-05	CcSEcCtD
Aripiprazole—Decreased appetite—Prednisone—prostate cancer	1.39e-05	5.67e-05	CcSEcCtD
Aripiprazole—Dysgeusia—Doxorubicin—prostate cancer	1.39e-05	5.67e-05	CcSEcCtD
Aripiprazole—Malaise—Epirubicin—prostate cancer	1.39e-05	5.64e-05	CcSEcCtD
Aripiprazole—Fatigue—Prednisone—prostate cancer	1.38e-05	5.63e-05	CcSEcCtD
Aripiprazole—Nervousness—Doxorubicin—prostate cancer	1.38e-05	5.62e-05	CcSEcCtD
Aripiprazole—Vertigo—Epirubicin—prostate cancer	1.38e-05	5.62e-05	CcSEcCtD
Aripiprazole—Syncope—Epirubicin—prostate cancer	1.38e-05	5.61e-05	CcSEcCtD
Aripiprazole—Leukopenia—Epirubicin—prostate cancer	1.38e-05	5.6e-05	CcSEcCtD
Aripiprazole—Back pain—Doxorubicin—prostate cancer	1.38e-05	5.6e-05	CcSEcCtD
Aripiprazole—Constipation—Prednisone—prostate cancer	1.37e-05	5.58e-05	CcSEcCtD
Aripiprazole—Hypersensitivity—Docetaxel—prostate cancer	1.37e-05	5.58e-05	CcSEcCtD
Aripiprazole—Muscle spasms—Doxorubicin—prostate cancer	1.37e-05	5.56e-05	CcSEcCtD
Aripiprazole—Palpitations—Epirubicin—prostate cancer	1.36e-05	5.53e-05	CcSEcCtD
Aripiprazole—Loss of consciousness—Epirubicin—prostate cancer	1.35e-05	5.5e-05	CcSEcCtD
Aripiprazole—Cough—Epirubicin—prostate cancer	1.34e-05	5.46e-05	CcSEcCtD
Aripiprazole—Vision blurred—Doxorubicin—prostate cancer	1.34e-05	5.45e-05	CcSEcCtD
Aripiprazole—Asthenia—Docetaxel—prostate cancer	1.33e-05	5.43e-05	CcSEcCtD
Aripiprazole—Convulsion—Epirubicin—prostate cancer	1.33e-05	5.42e-05	CcSEcCtD
Aripiprazole—Nausea—Etoposide—prostate cancer	1.33e-05	5.41e-05	CcSEcCtD
Aripiprazole—Hypertension—Epirubicin—prostate cancer	1.33e-05	5.4e-05	CcSEcCtD
Aripiprazole—Hypersensitivity—Capecitabine—prostate cancer	1.33e-05	5.4e-05	CcSEcCtD
Aripiprazole—Feeling abnormal—Prednisone—prostate cancer	1.32e-05	5.38e-05	CcSEcCtD
Aripiprazole—Ill-defined disorder—Doxorubicin—prostate cancer	1.32e-05	5.37e-05	CcSEcCtD
Aripiprazole—Pruritus—Docetaxel—prostate cancer	1.32e-05	5.35e-05	CcSEcCtD
Aripiprazole—Anaemia—Doxorubicin—prostate cancer	1.31e-05	5.35e-05	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Prednisone—prostate cancer	1.31e-05	5.34e-05	CcSEcCtD
Aripiprazole—Arthralgia—Epirubicin—prostate cancer	1.31e-05	5.32e-05	CcSEcCtD
Aripiprazole—Myalgia—Epirubicin—prostate cancer	1.31e-05	5.32e-05	CcSEcCtD
Aripiprazole—Chest pain—Epirubicin—prostate cancer	1.31e-05	5.32e-05	CcSEcCtD
Aripiprazole—Agitation—Doxorubicin—prostate cancer	1.31e-05	5.32e-05	CcSEcCtD
Aripiprazole—Anxiety—Epirubicin—prostate cancer	1.3e-05	5.31e-05	CcSEcCtD
Aripiprazole—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	1.3e-05	5.29e-05	CcSEcCtD
Aripiprazole—Discomfort—Epirubicin—prostate cancer	1.29e-05	5.26e-05	CcSEcCtD
Aripiprazole—Asthenia—Capecitabine—prostate cancer	1.29e-05	5.26e-05	CcSEcCtD
Aripiprazole—Malaise—Doxorubicin—prostate cancer	1.28e-05	5.22e-05	CcSEcCtD
Aripiprazole—Dry mouth—Epirubicin—prostate cancer	1.28e-05	5.21e-05	CcSEcCtD
Aripiprazole—Vertigo—Doxorubicin—prostate cancer	1.28e-05	5.2e-05	CcSEcCtD
Aripiprazole—Syncope—Doxorubicin—prostate cancer	1.27e-05	5.19e-05	CcSEcCtD
Aripiprazole—Urticaria—Prednisone—prostate cancer	1.27e-05	5.18e-05	CcSEcCtD
Aripiprazole—Pruritus—Capecitabine—prostate cancer	1.27e-05	5.18e-05	CcSEcCtD
Aripiprazole—Leukopenia—Doxorubicin—prostate cancer	1.27e-05	5.18e-05	CcSEcCtD
Aripiprazole—Diarrhoea—Docetaxel—prostate cancer	1.27e-05	5.18e-05	CcSEcCtD
Aripiprazole—Abdominal pain—Prednisone—prostate cancer	1.27e-05	5.16e-05	CcSEcCtD
Aripiprazole—Body temperature increased—Prednisone—prostate cancer	1.27e-05	5.16e-05	CcSEcCtD
Aripiprazole—Confusional state—Epirubicin—prostate cancer	1.26e-05	5.15e-05	CcSEcCtD
Aripiprazole—Palpitations—Doxorubicin—prostate cancer	1.26e-05	5.11e-05	CcSEcCtD
Aripiprazole—Oedema—Epirubicin—prostate cancer	1.25e-05	5.1e-05	CcSEcCtD
Aripiprazole—Anaphylactic shock—Epirubicin—prostate cancer	1.25e-05	5.1e-05	CcSEcCtD
Aripiprazole—Loss of consciousness—Doxorubicin—prostate cancer	1.25e-05	5.09e-05	CcSEcCtD
Aripiprazole—Infection—Epirubicin—prostate cancer	1.25e-05	5.07e-05	CcSEcCtD
Aripiprazole—Cough—Doxorubicin—prostate cancer	1.24e-05	5.05e-05	CcSEcCtD
Aripiprazole—Shock—Epirubicin—prostate cancer	1.23e-05	5.02e-05	CcSEcCtD
Aripiprazole—Convulsion—Doxorubicin—prostate cancer	1.23e-05	5.01e-05	CcSEcCtD
Aripiprazole—Diarrhoea—Capecitabine—prostate cancer	1.23e-05	5.01e-05	CcSEcCtD
Aripiprazole—Nervous system disorder—Epirubicin—prostate cancer	1.23e-05	5.01e-05	CcSEcCtD
Aripiprazole—Dizziness—Docetaxel—prostate cancer	1.23e-05	5e-05	CcSEcCtD
Aripiprazole—Thrombocytopenia—Epirubicin—prostate cancer	1.23e-05	5e-05	CcSEcCtD
Aripiprazole—Hypertension—Doxorubicin—prostate cancer	1.23e-05	5e-05	CcSEcCtD
Aripiprazole—Tachycardia—Epirubicin—prostate cancer	1.22e-05	4.98e-05	CcSEcCtD
Aripiprazole—Skin disorder—Epirubicin—prostate cancer	1.22e-05	4.96e-05	CcSEcCtD
Aripiprazole—Hyperhidrosis—Epirubicin—prostate cancer	1.21e-05	4.93e-05	CcSEcCtD
Aripiprazole—Arthralgia—Doxorubicin—prostate cancer	1.21e-05	4.93e-05	CcSEcCtD
Aripiprazole—Chest pain—Doxorubicin—prostate cancer	1.21e-05	4.93e-05	CcSEcCtD
Aripiprazole—Myalgia—Doxorubicin—prostate cancer	1.21e-05	4.93e-05	CcSEcCtD
Aripiprazole—Anxiety—Doxorubicin—prostate cancer	1.21e-05	4.91e-05	CcSEcCtD
Aripiprazole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	1.2e-05	4.89e-05	CcSEcCtD
Aripiprazole—Discomfort—Doxorubicin—prostate cancer	1.2e-05	4.87e-05	CcSEcCtD
Aripiprazole—Anorexia—Epirubicin—prostate cancer	1.2e-05	4.87e-05	CcSEcCtD
Aripiprazole—Dizziness—Capecitabine—prostate cancer	1.19e-05	4.85e-05	CcSEcCtD
Aripiprazole—Dry mouth—Doxorubicin—prostate cancer	1.18e-05	4.82e-05	CcSEcCtD
Aripiprazole—Vomiting—Docetaxel—prostate cancer	1.18e-05	4.81e-05	CcSEcCtD
Aripiprazole—Hypersensitivity—Prednisone—prostate cancer	1.18e-05	4.81e-05	CcSEcCtD
Aripiprazole—Rash—Docetaxel—prostate cancer	1.17e-05	4.77e-05	CcSEcCtD
Aripiprazole—Hypotension—Epirubicin—prostate cancer	1.17e-05	4.77e-05	CcSEcCtD
Aripiprazole—Dermatitis—Docetaxel—prostate cancer	1.17e-05	4.77e-05	CcSEcCtD
Aripiprazole—Confusional state—Doxorubicin—prostate cancer	1.17e-05	4.76e-05	CcSEcCtD
Aripiprazole—Headache—Docetaxel—prostate cancer	1.16e-05	4.74e-05	CcSEcCtD
Aripiprazole—Anaphylactic shock—Doxorubicin—prostate cancer	1.16e-05	4.72e-05	CcSEcCtD
Aripiprazole—Oedema—Doxorubicin—prostate cancer	1.16e-05	4.72e-05	CcSEcCtD
Aripiprazole—Infection—Doxorubicin—prostate cancer	1.15e-05	4.69e-05	CcSEcCtD
Aripiprazole—Asthenia—Prednisone—prostate cancer	1.15e-05	4.68e-05	CcSEcCtD
Aripiprazole—Vomiting—Capecitabine—prostate cancer	1.14e-05	4.66e-05	CcSEcCtD
Aripiprazole—Musculoskeletal discomfort—Epirubicin—prostate cancer	1.14e-05	4.65e-05	CcSEcCtD
Aripiprazole—Shock—Doxorubicin—prostate cancer	1.14e-05	4.65e-05	CcSEcCtD
Aripiprazole—Nervous system disorder—Doxorubicin—prostate cancer	1.14e-05	4.63e-05	CcSEcCtD
Aripiprazole—Thrombocytopenia—Doxorubicin—prostate cancer	1.14e-05	4.62e-05	CcSEcCtD
Aripiprazole—Rash—Capecitabine—prostate cancer	1.13e-05	4.62e-05	CcSEcCtD
Aripiprazole—Pruritus—Prednisone—prostate cancer	1.13e-05	4.62e-05	CcSEcCtD
Aripiprazole—Insomnia—Epirubicin—prostate cancer	1.13e-05	4.62e-05	CcSEcCtD
Aripiprazole—Dermatitis—Capecitabine—prostate cancer	1.13e-05	4.62e-05	CcSEcCtD
Aripiprazole—Tachycardia—Doxorubicin—prostate cancer	1.13e-05	4.61e-05	CcSEcCtD
Aripiprazole—Headache—Capecitabine—prostate cancer	1.13e-05	4.59e-05	CcSEcCtD
Aripiprazole—Skin disorder—Doxorubicin—prostate cancer	1.13e-05	4.59e-05	CcSEcCtD
Aripiprazole—Paraesthesia—Epirubicin—prostate cancer	1.13e-05	4.58e-05	CcSEcCtD
Aripiprazole—Hyperhidrosis—Doxorubicin—prostate cancer	1.12e-05	4.57e-05	CcSEcCtD
Aripiprazole—Dyspnoea—Epirubicin—prostate cancer	1.12e-05	4.55e-05	CcSEcCtD
Aripiprazole—Somnolence—Epirubicin—prostate cancer	1.11e-05	4.54e-05	CcSEcCtD
Aripiprazole—Anorexia—Doxorubicin—prostate cancer	1.11e-05	4.5e-05	CcSEcCtD
Aripiprazole—Nausea—Docetaxel—prostate cancer	1.1e-05	4.5e-05	CcSEcCtD
Aripiprazole—Dyspepsia—Epirubicin—prostate cancer	1.1e-05	4.49e-05	CcSEcCtD
Aripiprazole—Diarrhoea—Prednisone—prostate cancer	1.1e-05	4.47e-05	CcSEcCtD
Aripiprazole—Decreased appetite—Epirubicin—prostate cancer	1.09e-05	4.44e-05	CcSEcCtD
Aripiprazole—Hypotension—Doxorubicin—prostate cancer	1.08e-05	4.41e-05	CcSEcCtD
Aripiprazole—Gastrointestinal disorder—Epirubicin—prostate cancer	1.08e-05	4.41e-05	CcSEcCtD
Aripiprazole—Fatigue—Epirubicin—prostate cancer	1.08e-05	4.4e-05	CcSEcCtD
Aripiprazole—Pain—Epirubicin—prostate cancer	1.07e-05	4.36e-05	CcSEcCtD
Aripiprazole—Constipation—Epirubicin—prostate cancer	1.07e-05	4.36e-05	CcSEcCtD
Aripiprazole—Nausea—Capecitabine—prostate cancer	1.07e-05	4.35e-05	CcSEcCtD
Aripiprazole—Dizziness—Prednisone—prostate cancer	1.06e-05	4.32e-05	CcSEcCtD
Aripiprazole—Musculoskeletal discomfort—Doxorubicin—prostate cancer	1.06e-05	4.3e-05	CcSEcCtD
Aripiprazole—Insomnia—Doxorubicin—prostate cancer	1.05e-05	4.27e-05	CcSEcCtD
Aripiprazole—Paraesthesia—Doxorubicin—prostate cancer	1.04e-05	4.24e-05	CcSEcCtD
Aripiprazole—Dyspnoea—Doxorubicin—prostate cancer	1.03e-05	4.21e-05	CcSEcCtD
Aripiprazole—Feeling abnormal—Epirubicin—prostate cancer	1.03e-05	4.21e-05	CcSEcCtD
Aripiprazole—Somnolence—Doxorubicin—prostate cancer	1.03e-05	4.2e-05	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Epirubicin—prostate cancer	1.03e-05	4.17e-05	CcSEcCtD
Aripiprazole—Dyspepsia—Doxorubicin—prostate cancer	1.02e-05	4.16e-05	CcSEcCtD
Aripiprazole—Vomiting—Prednisone—prostate cancer	1.02e-05	4.15e-05	CcSEcCtD
Aripiprazole—Rash—Prednisone—prostate cancer	1.01e-05	4.12e-05	CcSEcCtD
Aripiprazole—Dermatitis—Prednisone—prostate cancer	1.01e-05	4.11e-05	CcSEcCtD
Aripiprazole—Decreased appetite—Doxorubicin—prostate cancer	1.01e-05	4.11e-05	CcSEcCtD
Aripiprazole—Headache—Prednisone—prostate cancer	1e-05	4.09e-05	CcSEcCtD
Aripiprazole—Gastrointestinal disorder—Doxorubicin—prostate cancer	1e-05	4.08e-05	CcSEcCtD
Aripiprazole—Fatigue—Doxorubicin—prostate cancer	1e-05	4.07e-05	CcSEcCtD
Aripiprazole—Urticaria—Epirubicin—prostate cancer	9.96e-06	4.05e-05	CcSEcCtD
Aripiprazole—Pain—Doxorubicin—prostate cancer	9.92e-06	4.04e-05	CcSEcCtD
Aripiprazole—Constipation—Doxorubicin—prostate cancer	9.92e-06	4.04e-05	CcSEcCtD
Aripiprazole—Abdominal pain—Epirubicin—prostate cancer	9.91e-06	4.04e-05	CcSEcCtD
Aripiprazole—Body temperature increased—Epirubicin—prostate cancer	9.91e-06	4.04e-05	CcSEcCtD
Aripiprazole—Feeling abnormal—Doxorubicin—prostate cancer	9.56e-06	3.89e-05	CcSEcCtD
Aripiprazole—Nausea—Prednisone—prostate cancer	9.52e-06	3.88e-05	CcSEcCtD
Aripiprazole—Gastrointestinal pain—Doxorubicin—prostate cancer	9.49e-06	3.86e-05	CcSEcCtD
Aripiprazole—Hypersensitivity—Epirubicin—prostate cancer	9.24e-06	3.76e-05	CcSEcCtD
Aripiprazole—Urticaria—Doxorubicin—prostate cancer	9.22e-06	3.75e-05	CcSEcCtD
Aripiprazole—Abdominal pain—Doxorubicin—prostate cancer	9.17e-06	3.73e-05	CcSEcCtD
Aripiprazole—Body temperature increased—Doxorubicin—prostate cancer	9.17e-06	3.73e-05	CcSEcCtD
Aripiprazole—Asthenia—Epirubicin—prostate cancer	9e-06	3.66e-05	CcSEcCtD
Aripiprazole—Pruritus—Epirubicin—prostate cancer	8.87e-06	3.61e-05	CcSEcCtD
Aripiprazole—Diarrhoea—Epirubicin—prostate cancer	8.58e-06	3.49e-05	CcSEcCtD
Aripiprazole—Hypersensitivity—Doxorubicin—prostate cancer	8.55e-06	3.48e-05	CcSEcCtD
Aripiprazole—Asthenia—Doxorubicin—prostate cancer	8.32e-06	3.39e-05	CcSEcCtD
Aripiprazole—Dizziness—Epirubicin—prostate cancer	8.29e-06	3.38e-05	CcSEcCtD
Aripiprazole—Pruritus—Doxorubicin—prostate cancer	8.21e-06	3.34e-05	CcSEcCtD
Aripiprazole—Vomiting—Epirubicin—prostate cancer	7.97e-06	3.25e-05	CcSEcCtD
Aripiprazole—Diarrhoea—Doxorubicin—prostate cancer	7.94e-06	3.23e-05	CcSEcCtD
Aripiprazole—Rash—Epirubicin—prostate cancer	7.91e-06	3.22e-05	CcSEcCtD
Aripiprazole—Dermatitis—Epirubicin—prostate cancer	7.9e-06	3.22e-05	CcSEcCtD
Aripiprazole—Headache—Epirubicin—prostate cancer	7.86e-06	3.2e-05	CcSEcCtD
Aripiprazole—Dizziness—Doxorubicin—prostate cancer	7.67e-06	3.12e-05	CcSEcCtD
Aripiprazole—Nausea—Epirubicin—prostate cancer	7.45e-06	3.03e-05	CcSEcCtD
Aripiprazole—Vomiting—Doxorubicin—prostate cancer	7.38e-06	3e-05	CcSEcCtD
Aripiprazole—Rash—Doxorubicin—prostate cancer	7.32e-06	2.98e-05	CcSEcCtD
Aripiprazole—Dermatitis—Doxorubicin—prostate cancer	7.31e-06	2.98e-05	CcSEcCtD
Aripiprazole—Headache—Doxorubicin—prostate cancer	7.27e-06	2.96e-05	CcSEcCtD
Aripiprazole—Nausea—Doxorubicin—prostate cancer	6.89e-06	2.81e-05	CcSEcCtD
Aripiprazole—HTR2A—Signaling Pathways—PTEN—prostate cancer	1.04e-06	8.69e-06	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—PIK3CD—prostate cancer	1.04e-06	8.68e-06	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—PTEN—prostate cancer	1.04e-06	8.67e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—MMP9—prostate cancer	1.04e-06	8.66e-06	CbGpPWpGaD
Aripiprazole—CYP3A5—Metabolism—PTEN—prostate cancer	1.04e-06	8.66e-06	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—CDKN1A—prostate cancer	1.04e-06	8.66e-06	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—PIK3CA—prostate cancer	1.04e-06	8.66e-06	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—MYC—prostate cancer	1.04e-06	8.66e-06	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—VEGFA—prostate cancer	1.04e-06	8.65e-06	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—PTEN—prostate cancer	1.04e-06	8.64e-06	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—TGFB1—prostate cancer	1.04e-06	8.63e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—CDKN1A—prostate cancer	1.04e-06	8.63e-06	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—CREBBP—prostate cancer	1.03e-06	8.62e-06	CbGpPWpGaD
Aripiprazole—DRD2—Signaling by GPCR—AKT1—prostate cancer	1.03e-06	8.61e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—PTEN—prostate cancer	1.03e-06	8.61e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—CDKN1B—prostate cancer	1.03e-06	8.58e-06	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—MMP9—prostate cancer	1.03e-06	8.58e-06	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—STAT3—prostate cancer	1.03e-06	8.56e-06	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—MMP9—prostate cancer	1.03e-06	8.55e-06	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—CDKN1A—prostate cancer	1.03e-06	8.55e-06	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—EGFR—prostate cancer	1.02e-06	8.54e-06	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—PTEN—prostate cancer	1.02e-06	8.53e-06	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—CDKN1A—prostate cancer	1.02e-06	8.52e-06	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—PTEN—prostate cancer	1.02e-06	8.5e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—GPCR downstream signaling—AKT1—prostate cancer	1.02e-06	8.49e-06	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—IL6—prostate cancer	1.02e-06	8.48e-06	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—IL6—prostate cancer	1.02e-06	8.48e-06	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling by GPCR—AKT1—prostate cancer	1.02e-06	8.47e-06	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—EGFR—prostate cancer	1.02e-06	8.47e-06	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—TP53—prostate cancer	1.01e-06	8.46e-06	CbGpPWpGaD
Aripiprazole—HRH1—Signaling by GPCR—AKT1—prostate cancer	1.01e-06	8.46e-06	CbGpPWpGaD
Aripiprazole—CYP3A7—Metabolism—PIK3CA—prostate cancer	1.01e-06	8.45e-06	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling by GPCR—AKT1—prostate cancer	1.01e-06	8.43e-06	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—IL6—prostate cancer	1.01e-06	8.42e-06	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—EP300—prostate cancer	1.01e-06	8.42e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—CASP3—prostate cancer	1.01e-06	8.41e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling by GPCR—AKT1—prostate cancer	1.01e-06	8.4e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—IL2—prostate cancer	1.01e-06	8.4e-06	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—TP53—prostate cancer	1e-06	8.37e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling by GPCR—IL6—prostate cancer	1e-06	8.36e-06	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—MYC—prostate cancer	1e-06	8.36e-06	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—TGFB1—prostate cancer	1e-06	8.33e-06	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling by GPCR—AKT1—prostate cancer	9.98e-07	8.32e-06	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—MYC—prostate cancer	9.97e-07	8.31e-06	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling by GPCR—AKT1—prostate cancer	9.95e-07	8.3e-06	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—TGFB1—prostate cancer	9.95e-07	8.29e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—TYMS—prostate cancer	9.94e-07	8.28e-06	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—EP300—prostate cancer	9.94e-07	8.28e-06	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—EP300—prostate cancer	9.91e-07	8.27e-06	CbGpPWpGaD
Aripiprazole—CYP3A5—Metabolism—EP300—prostate cancer	9.91e-07	8.26e-06	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—PIK3CA—prostate cancer	9.89e-07	8.25e-06	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—IL6—prostate cancer	9.89e-07	8.24e-06	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—EP300—prostate cancer	9.88e-07	8.24e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—EP300—prostate cancer	9.85e-07	8.21e-06	CbGpPWpGaD
Aripiprazole—ADRA2C—Metabolism—PIK3CA—prostate cancer	9.85e-07	8.21e-06	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—NOS3—prostate cancer	9.83e-07	8.19e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—GSTM1—prostate cancer	9.82e-07	8.19e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—CCND1—prostate cancer	9.82e-07	8.19e-06	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—SRC—prostate cancer	9.82e-07	8.19e-06	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—PIK3CD—prostate cancer	9.81e-07	8.18e-06	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—EGFR—prostate cancer	9.8e-07	8.17e-06	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—PIK3CA—prostate cancer	9.76e-07	8.14e-06	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—EP300—prostate cancer	9.76e-07	8.13e-06	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—EGFR—prostate cancer	9.75e-07	8.13e-06	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—IL6—prostate cancer	9.73e-07	8.11e-06	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—EP300—prostate cancer	9.73e-07	8.11e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—CTNNB1—prostate cancer	9.72e-07	8.11e-06	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—MYC—prostate cancer	9.7e-07	8.08e-06	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—KRAS—prostate cancer	9.68e-07	8.07e-06	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—TGFB1—prostate cancer	9.67e-07	8.07e-06	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—SRC—prostate cancer	9.66e-07	8.05e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—LPL—prostate cancer	9.64e-07	8.04e-06	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—SRC—prostate cancer	9.64e-07	8.04e-06	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—SRC—prostate cancer	9.61e-07	8.01e-06	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—IL6—prostate cancer	9.6e-07	8e-06	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—KRAS—prostate cancer	9.59e-07	8e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—SRC—prostate cancer	9.58e-07	7.99e-06	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—TP53—prostate cancer	9.57e-07	7.98e-06	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—VEGFA—prostate cancer	9.56e-07	7.97e-06	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—MYC—prostate cancer	9.54e-07	7.96e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—MMP9—prostate cancer	9.53e-07	7.95e-06	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—TGFB1—prostate cancer	9.52e-07	7.94e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—CDKN1A—prostate cancer	9.5e-07	7.92e-06	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—SRC—prostate cancer	9.49e-07	7.91e-06	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—EGFR—prostate cancer	9.49e-07	7.91e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—PTEN—prostate cancer	9.48e-07	7.9e-06	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—STAT3—prostate cancer	9.47e-07	7.89e-06	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—SRC—prostate cancer	9.46e-07	7.89e-06	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—TP53—prostate cancer	9.44e-07	7.87e-06	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—VEGFA—prostate cancer	9.41e-07	7.85e-06	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—VEGFA—prostate cancer	9.39e-07	7.83e-06	CbGpPWpGaD
Aripiprazole—HTR6—Signaling Pathways—AKT1—prostate cancer	9.39e-07	7.83e-06	CbGpPWpGaD
Aripiprazole—HTR7—Signaling Pathways—AKT1—prostate cancer	9.38e-07	7.82e-06	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—VEGFA—prostate cancer	9.36e-07	7.8e-06	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—EGFR—prostate cancer	9.33e-07	7.78e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—VEGFA—prostate cancer	9.33e-07	7.78e-06	CbGpPWpGaD
Aripiprazole—HTR1D—Signaling Pathways—AKT1—prostate cancer	9.32e-07	7.77e-06	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—STAT3—prostate cancer	9.32e-07	7.77e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—CYP1A1—prostate cancer	9.31e-07	7.76e-06	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—STAT3—prostate cancer	9.3e-07	7.75e-06	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—IL6—prostate cancer	9.29e-07	7.74e-06	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—STAT3—prostate cancer	9.27e-07	7.73e-06	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—NOS3—prostate cancer	9.26e-07	7.72e-06	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—KRAS—prostate cancer	9.26e-07	7.72e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling by GPCR—AKT1—prostate cancer	9.25e-07	7.71e-06	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—VEGFA—prostate cancer	9.24e-07	7.7e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—STAT3—prostate cancer	9.24e-07	7.7e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—ERCC2—prostate cancer	9.23e-07	7.7e-06	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—VEGFA—prostate cancer	9.21e-07	7.68e-06	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—KRAS—prostate cancer	9.21e-07	7.68e-06	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—IL6—prostate cancer	9.19e-07	7.66e-06	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—STAT3—prostate cancer	9.15e-07	7.63e-06	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—STAT3—prostate cancer	9.12e-07	7.61e-06	CbGpPWpGaD
Aripiprazole—HTR1B—Signaling Pathways—AKT1—prostate cancer	9.12e-07	7.61e-06	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—PIK3CB—prostate cancer	9.07e-07	7.56e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—EP300—prostate cancer	9.04e-07	7.54e-06	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—PTGS2—prostate cancer	8.99e-07	7.49e-06	CbGpPWpGaD
Aripiprazole—DRD4—Signaling Pathways—AKT1—prostate cancer	8.98e-07	7.48e-06	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—KRAS—prostate cancer	8.96e-07	7.47e-06	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—PIK3CA—prostate cancer	8.89e-07	7.42e-06	CbGpPWpGaD
Aripiprazole—CHRM4—Signaling Pathways—AKT1—prostate cancer	8.86e-07	7.38e-06	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—KRAS—prostate cancer	8.82e-07	7.35e-06	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—PIK3CA—prostate cancer	8.81e-07	7.35e-06	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—MYC—prostate cancer	8.8e-07	7.34e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—SRC—prostate cancer	8.79e-07	7.33e-06	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—TGFB1—prostate cancer	8.78e-07	7.32e-06	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—IL6—prostate cancer	8.76e-07	7.3e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Metabolism—PIK3CA—prostate cancer	8.71e-07	7.27e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—MTHFR—prostate cancer	8.68e-07	7.24e-06	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—MYC—prostate cancer	8.66e-07	7.22e-06	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—IL6—prostate cancer	8.64e-07	7.21e-06	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—MYC—prostate cancer	8.64e-07	7.2e-06	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—TGFB1—prostate cancer	8.64e-07	7.2e-06	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—TGFB1—prostate cancer	8.62e-07	7.19e-06	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—MYC—prostate cancer	8.61e-07	7.18e-06	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—EGFR—prostate cancer	8.61e-07	7.18e-06	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—TP53—prostate cancer	8.6e-07	7.17e-06	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—TGFB1—prostate cancer	8.59e-07	7.16e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—MYC—prostate cancer	8.58e-07	7.16e-06	CbGpPWpGaD
Aripiprazole—HTR2B—Signaling Pathways—AKT1—prostate cancer	8.57e-07	7.15e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—TGFB1—prostate cancer	8.56e-07	7.14e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—VEGFA—prostate cancer	8.56e-07	7.14e-06	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—PIK3CB—prostate cancer	8.55e-07	7.13e-06	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—TP53—prostate cancer	8.53e-07	7.11e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—PPARA—prostate cancer	8.52e-07	7.1e-06	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—PIK3CA—prostate cancer	8.51e-07	7.09e-06	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—MYC—prostate cancer	8.5e-07	7.09e-06	CbGpPWpGaD
Aripiprazole—CHRM5—Signaling Pathways—AKT1—prostate cancer	8.48e-07	7.07e-06	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—TGFB1—prostate cancer	8.48e-07	7.07e-06	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—MYC—prostate cancer	8.48e-07	7.07e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—STAT3—prostate cancer	8.48e-07	7.07e-06	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—PTGS2—prostate cancer	8.47e-07	7.06e-06	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—EGFR—prostate cancer	8.47e-07	7.06e-06	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—PIK3CA—prostate cancer	8.46e-07	7.06e-06	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—TGFB1—prostate cancer	8.46e-07	7.05e-06	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—EGFR—prostate cancer	8.45e-07	7.04e-06	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—EGFR—prostate cancer	8.42e-07	7.02e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—EGFR—prostate cancer	8.4e-07	7e-06	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—EGFR—prostate cancer	8.31e-07	6.93e-06	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—EGFR—prostate cancer	8.29e-07	6.91e-06	CbGpPWpGaD
Aripiprazole—CYP3A7—Metabolism—AKT1—prostate cancer	8.28e-07	6.9e-06	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—PIK3CA—prostate cancer	8.23e-07	6.86e-06	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—TP53—prostate cancer	8.23e-07	6.86e-06	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—TP53—prostate cancer	8.19e-07	6.83e-06	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—KRAS—prostate cancer	8.13e-07	6.78e-06	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—PIK3CA—prostate cancer	8.1e-07	6.75e-06	CbGpPWpGaD
Aripiprazole—DRD1—Signaling Pathways—AKT1—prostate cancer	8.08e-07	6.74e-06	CbGpPWpGaD
Aripiprazole—ADRA2C—Metabolism—AKT1—prostate cancer	8.04e-07	6.71e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—CAV1—prostate cancer	8.01e-07	6.68e-06	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—KRAS—prostate cancer	8e-07	6.67e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Metabolism—PIK3CA—prostate cancer	8e-07	6.67e-06	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—KRAS—prostate cancer	7.98e-07	6.66e-06	CbGpPWpGaD
Aripiprazole—DRD3—Signaling Pathways—AKT1—prostate cancer	7.97e-07	6.65e-06	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—TP53—prostate cancer	7.96e-07	6.64e-06	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—KRAS—prostate cancer	7.96e-07	6.63e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—KRAS—prostate cancer	7.93e-07	6.61e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—MYC—prostate cancer	7.88e-07	6.57e-06	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—IL6—prostate cancer	7.88e-07	6.57e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—TGFB1—prostate cancer	7.86e-07	6.55e-06	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—KRAS—prostate cancer	7.85e-07	6.55e-06	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—PTEN—prostate cancer	7.84e-07	6.53e-06	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—TP53—prostate cancer	7.84e-07	6.53e-06	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—KRAS—prostate cancer	7.83e-07	6.53e-06	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—IL6—prostate cancer	7.8e-07	6.51e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—EGFR—prostate cancer	7.7e-07	6.42e-06	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—IL6—prostate cancer	7.53e-07	6.28e-06	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—IL6—prostate cancer	7.49e-07	6.25e-06	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—EP300—prostate cancer	7.48e-07	6.23e-06	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—PIK3CA—prostate cancer	7.47e-07	6.23e-06	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—PTEN—prostate cancer	7.39e-07	6.16e-06	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—PIK3CA—prostate cancer	7.35e-07	6.13e-06	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—PIK3CA—prostate cancer	7.33e-07	6.11e-06	CbGpPWpGaD
Aripiprazole—CYP3A5—Metabolism—PIK3CA—prostate cancer	7.33e-07	6.11e-06	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—PIK3CA—prostate cancer	7.31e-07	6.09e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—PIK3CG—prostate cancer	7.29e-07	6.08e-06	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—IL6—prostate cancer	7.29e-07	6.08e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—PIK3CA—prostate cancer	7.29e-07	6.08e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—KRAS—prostate cancer	7.28e-07	6.07e-06	CbGpPWpGaD
Aripiprazole—ADRB1—Signaling Pathways—AKT1—prostate cancer	7.27e-07	6.06e-06	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—TP53—prostate cancer	7.23e-07	6.02e-06	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—PIK3CA—prostate cancer	7.22e-07	6.02e-06	CbGpPWpGaD
Aripiprazole—ADRA2B—Signaling Pathways—AKT1—prostate cancer	7.2e-07	6e-06	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—PIK3CA—prostate cancer	7.2e-07	6e-06	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—IL6—prostate cancer	7.17e-07	5.98e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Metabolism—AKT1—prostate cancer	7.12e-07	5.94e-06	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—TP53—prostate cancer	7.11e-07	5.93e-06	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—TP53—prostate cancer	7.09e-07	5.92e-06	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—TP53—prostate cancer	7.07e-07	5.9e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—TP53—prostate cancer	7.05e-07	5.88e-06	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—EP300—prostate cancer	7.04e-07	5.87e-06	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—TP53—prostate cancer	6.98e-07	5.82e-06	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—TP53—prostate cancer	6.96e-07	5.8e-06	CbGpPWpGaD
Aripiprazole—HTR1A—Signaling Pathways—AKT1—prostate cancer	6.95e-07	5.79e-06	CbGpPWpGaD
Aripiprazole—HTR2C—Signaling Pathways—AKT1—prostate cancer	6.91e-07	5.76e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—INS—prostate cancer	6.9e-07	5.76e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—CREBBP—prostate cancer	6.76e-07	5.64e-06	CbGpPWpGaD
Aripiprazole—ADRA2C—Signaling Pathways—AKT1—prostate cancer	6.72e-07	5.61e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—PIK3CA—prostate cancer	6.69e-07	5.57e-06	CbGpPWpGaD
Aripiprazole—ADRA1B—Signaling Pathways—AKT1—prostate cancer	6.62e-07	5.52e-06	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—IL6—prostate cancer	6.61e-07	5.51e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Metabolism—AKT1—prostate cancer	6.53e-07	5.45e-06	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—IL6—prostate cancer	6.51e-07	5.43e-06	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—IL6—prostate cancer	6.49e-07	5.41e-06	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—IL6—prostate cancer	6.47e-07	5.4e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—TP53—prostate cancer	6.47e-07	5.39e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—IL6—prostate cancer	6.45e-07	5.38e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—PIK3CD—prostate cancer	6.41e-07	5.35e-06	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—IL6—prostate cancer	6.39e-07	5.33e-06	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—IL6—prostate cancer	6.37e-07	5.31e-06	CbGpPWpGaD
Aripiprazole—DRD2—Signaling Pathways—AKT1—prostate cancer	6.1e-07	5.09e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—NOS3—prostate cancer	6.05e-07	5.05e-06	CbGpPWpGaD
Aripiprazole—HTR2A—Signaling Pathways—AKT1—prostate cancer	6e-07	5.01e-06	CbGpPWpGaD
Aripiprazole—HRH1—Signaling Pathways—AKT1—prostate cancer	5.99e-07	4.99e-06	CbGpPWpGaD
Aripiprazole—CYP3A5—Metabolism—AKT1—prostate cancer	5.99e-07	4.99e-06	CbGpPWpGaD
Aripiprazole—CHRM1—Signaling Pathways—AKT1—prostate cancer	5.97e-07	4.98e-06	CbGpPWpGaD
Aripiprazole—CHRM3—Signaling Pathways—AKT1—prostate cancer	5.95e-07	4.96e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—IL6—prostate cancer	5.92e-07	4.94e-06	CbGpPWpGaD
Aripiprazole—CHRM2—Signaling Pathways—AKT1—prostate cancer	5.9e-07	4.91e-06	CbGpPWpGaD
Aripiprazole—ADRA1A—Signaling Pathways—AKT1—prostate cancer	5.88e-07	4.9e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—PIK3CB—prostate cancer	5.59e-07	4.66e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—PTGS2—prostate cancer	5.54e-07	4.62e-06	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—PIK3CA—prostate cancer	5.53e-07	4.61e-06	CbGpPWpGaD
Aripiprazole—ADRA2A—Signaling Pathways—AKT1—prostate cancer	5.46e-07	4.55e-06	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—PIK3CA—prostate cancer	5.21e-07	4.34e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—PTEN—prostate cancer	4.83e-07	4.03e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—EP300—prostate cancer	4.61e-07	3.84e-06	CbGpPWpGaD
Aripiprazole—ABCB1—Metabolism—AKT1—prostate cancer	4.52e-07	3.77e-06	CbGpPWpGaD
Aripiprazole—CYP2D6—Metabolism—AKT1—prostate cancer	4.26e-07	3.55e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—PIK3CA—prostate cancer	3.41e-07	2.84e-06	CbGpPWpGaD
Aripiprazole—CYP3A4—Metabolism—AKT1—prostate cancer	2.78e-07	2.32e-06	CbGpPWpGaD
